Recent studies have also demonstrated improved disease-free survival with adjuvant osimertinib in those with resected EGFR mutant lung cancer [109], and adjuvant atezolizumab in those with resected stage II-III PD-L1-positive NSCLC [114]. Here, EGFR is linked to lung cancer.